Updated April 13, 2026
GLP-1 Drug Pricing Trends: 2023–2026
How the price of every major GLP-1 drug has changed from April 2023 to April 2026 — list prices, what patients actually pay, and the key events that reshaped the market.
Three years ago, GLP-1 drugs were among the most expensive medications in America. Uninsured patients faced $900–$1,350/month price tags with no alternatives beyond compounding pharmacies operating under a shortage exemption. Today, the same drugs are available for $199–$299/month through manufacturer-direct programs — and in some cases, branded versions are now cheaper than compounded copies.
This didn't happen because manufacturers voluntarily lowered list prices. WAC (Wholesale Acquisition Cost) — the price manufacturers charge wholesalers — barely moved, and in Ozempic's case actually went up. Instead, a series of political, competitive, and regulatory forces created an entirely separate pricing layer: direct-to-consumer programs, government-negotiated deals, and subscription models that bypass the traditional pharmacy supply chain.
The charts below tell two very different stories: one of price stagnation (WAC), and one of dramatic deflation (what patients actually pay). Understanding the gap between them is essential to understanding where GLP-1 pricing goes next.
Key takeaway: List prices have been remarkably sticky. Wegovy's WAC has never changed from its 2021 launch price of $1,349/mo. Ozempic's WAC actually increased from $936 to $1,027 despite massive political pressure. Mounjaro froze after January 2024. Novo Nordisk has announced a ~50% WAC cut to $675/mo effective January 2027 — but only after self-pay and government prices had already dropped far below WAC.
Why WAC still matters: Even though few patients pay WAC directly, it remains the anchor for insurance reimbursement, pharmacy margins, and PBM rebate negotiations. A high WAC with large rebates allows manufacturers to fund copay assistance programs while maintaining headline revenue. Novo's decision to finally cut WAC in 2027 signals that the political cost of maintaining a >$1,000 list price has finally exceeded its financial benefit — especially with IRA-negotiated Medicare prices locking in at $274/mo regardless.
Lilly vs. Novo strategy divergence: Eli Lilly froze Mounjaro/Zepbound WAC after January 2024 and hasn't announced a future WAC cut — instead channeling price reductions through LillyDirect vials. Novo kept taking small WAC increases (3–3.5% annually) while building out NovoCare as a parallel distribution channel. Both reached similar endpoints (~$299–$349/mo self-pay) through very different paths.
Key takeaway: Self-pay prices collapsed from $875–$1,300/mo in early 2023 to $199–$299/mo by April 2026 — driven by NovoCare Pharmacy (March 2025), LillyDirect vials (August 2024), the Trump MFN deal (November 2025), and Wegovy's subscription program (March 2026). Wegovy's best self-pay price dropped 81% in three years while its WAC didn't move a penny.
Lilly moved first, Novo moved furthest: Eli Lilly broke the logjam in August 2024 by introducing single-dose Zepbound vials at $349/mo — a form-factor hack that sidestepped the pen supply chain. This forced Novo Nordisk to respond. By March 2025, NovoCare Pharmacy offered Wegovy at $499/mo. By November 2025, both companies were at ~$349/mo. By April 2026, Novo's subscription model ($249/mo) and intro offer ($199/mo) made it the self-pay price leader — a complete reversal from 2023, when Wegovy was the most expensive GLP-1 for cash-paying patients.
The convergence effect: Notice how all four drugs converge toward $249–$349/mo by late 2025. This isn't coincidence — it's the price point where manufacturers can still capture meaningful margin while competing with compounded alternatives ($200–$325/mo) and satisfying the Trump administration's MFN framework. The $245/mo Medicare target price appears to be the gravitational center for the entire market.
What this means for patients: If you're uninsured or underinsured in April 2026, the cheapest branded GLP-1 entry point is Ozempic at $199/mo (intro) or Foundayo at $149/mo (via LillyDirect). For ongoing treatment, Wegovy's 12-month subscription at $249/mo or LillyDirect vials at $299/mo are the best deals. The era of $1,000+/mo out-of-pocket for GLP-1 drugs is effectively over for patients willing to use manufacturer-direct channels.
Key takeaway: Compounded semaglutide (dashed line) held steady at $200–$325/mo throughout the period while branded prices crashed toward it. By April 2026, branded Ozempic's self-pay intro price ($199/mo) is actually cheaper than most compounded alternatives — a dramatic reversal that undercuts the compounding market's value proposition.
The compounding squeeze: Compounders face pressure from both sides. The FDA resolved the semaglutide shortage in February 2025 and is actively enforcing compounding wind-down deadlines. Simultaneously, branded self-pay prices have fallen into the compounding price range. The compounding market's main remaining advantages are accessibility (no insurance hassles) and flexibility (custom dosing). But the price advantage that drove the market's explosive growth from 2022–2024 has largely evaporated.
Why compounded prices rose: Compounded semaglutide actually got more expensive over this period ($200 to $325), driven by tighter API supply after the shortage resolution, increased regulatory compliance costs, and consolidation among telehealth platforms. The cheapest compounded options ($99–$150/mo) that proliferated in 2023–2024 have largely disappeared.
Key Pricing Events Timeline
FDA adds semaglutide to drug shortage list — compounding exemption begins
FDA adds tirzepatide to drug shortage list
Zepbound launches at $1,059/mo — 20% below Wegovy
FDA expands Wegovy for cardiovascular risk — unlocks Medicare coverage
Eli Lilly launches Zepbound single-dose vials at $349–$549/mo via LillyDirect
FDA resolves tirzepatide shortage
FDA resolves semaglutide shortage — compounding wind-down begins
NovoCare Pharmacy launches — Wegovy at $499/mo, all doses
NovoCare adds Ozempic at $499/mo
Trump MFN deal: Medicare $245/mo, TrumpRx $350/mo, $50 copay
Novo cuts NovoCare to $349/mo; launches $199 intro offer
LillyDirect cuts Zepbound vials to $299–$449/mo; oral Wegovy FDA-approved
TrumpRx.gov launches; Novo announces 2027 WAC cut to $675/mo
Wegovy subscription program launches at $249/mo (12-month)
Foundayo launches at $649/mo WAC; LillyDirect from $149/mo
What's Next: 2027 and Beyond
January 2027 is the next inflection point. Two major pricing changes take effect simultaneously: Novo Nordisk's WAC cut to ~$675/mo for Ozempic, Wegovy, and Rybelsus (~35–50% reduction from current levels), and CMS Round 2 IRA-negotiated Medicare prices of $274/mo for semaglutide products. For the first time, the gap between WAC and what patients pay will narrow significantly.
Oral GLP-1s will reshape the competitive landscape. Foundayo (orforglipron) launched at $649/mo WAC — roughly half of Wegovy's WAC — and its no-food-restriction convenience advantage could shift market share. Oral Wegovy is already available. As oral options gain formulary traction, the injectable-vs-pill dynamic will increasingly drive pricing decisions.
India's generic wave won't reach the US soon, but it's reshaping global expectations. With 26+ generic semaglutide brands available at $14–$50/mo in India, the political case for US prices above $300/mo becomes harder to sustain. Novo's tentative FDA approval for Apotex's generic semaglutide injection signals eventual US generic entry — but patents block actual market entry until the early 2030s.
Retatrutide and next-gen triple agonists (expected 2028 launch) will create a new pricing tier. If Eli Lilly prices retatrutide above current GLP-1 levels based on superior efficacy (~29% weight loss), it could re-anchor the high end of the market and relieve downward pressure on existing drugs.
The Medicare obesity bridge program (launching July 2026) will be the first broad test of government-funded GLP-1 coverage for weight loss. If it demonstrates cost-effectiveness and political viability, it could pave the way for permanent Medicare Part D obesity drug coverage — removing the statutory exclusion that has limited access for 65+ million beneficiaries.
How to Get the Lowest Price Today
| Situation | Best Option | Price |
|---|---|---|
| Commercial insurance covers GLP-1s | Any GLP-1 + manufacturer savings card | $25/mo |
| Medicare (diabetes) | Ozempic or Mounjaro via TrumpRx | $50/mo copay |
| Medicare (obesity, starting July 2026) | Wegovy or Zepbound via bridge program | $50/mo copay |
| Uninsured, new to GLP-1s | Foundayo via LillyDirect | $149/mo |
| Uninsured, want semaglutide specifically | Ozempic intro offer via NovoCare | $199/mo |
| Uninsured, long-term maintenance | Wegovy 12-month subscription | $249/mo |
| Uninsured, want tirzepatide | Zepbound vials via LillyDirect | $299/mo |
See our full April 2026 pricing guide for complete details and source citations for each option.
Methodology
List prices (WAC) are sourced from manufacturer pricing pages (novopricing.com, pricinginfo.lilly.com), Oregon Prescription Drug Affordability Board filings, 46brooklyn Research, and SEC filings. Self-pay prices reflect the lowest available manufacturer-direct or authorized discount program price at each time point — not retail pharmacy cash prices or GoodRx coupons. Compounded semaglutide prices represent the midpoint of typical telehealth platform pricing. All prices are monthly (28-day supply). See our current pricing guide for detailed source citations on every price channel, and individual drug pages (Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo) for drug-specific breakdowns.